TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03576599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid Injectable Product
Description: One Group are randomiced to Zoledronic Acid Injectable Product and one Group to Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01688596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine (0.25%) will be injected through the closed trocar incisions after completion of the laparoscopic hysterectomy case.
Study: NCT03450291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volatility task
Description: Participants complete a volatility task, with pupillometry; and a Wisconsin Card Sort Task.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volatility task
Description: Participants complete a volatility task, with pupillometry; and a Wisconsin Card Sort Task.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volatility task
Description: Participants complete a volatility task, with pupillometry; and a Wisconsin Card Sort Task.
Study: NCT02645760

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core stabilization exercise
Description: 7-weeks of core stabilization exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: 7-weeks of conventional treatment include therapeutic ultrasound and hot pack
Study: NCT02244320

Intervention type: DRUG
Intervention: Tamsulosin
Study: NCT02781142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imagery training
Description: The motor imagery training will be designed for the individual basis with following standard protocols. It will be applied two times a week for 8 weeks. The first one and/or two sessions will be performed in the clinic, the other will be performed at the patients' home with a video-conference telerehabilitation technique.
Study: NCT01518881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKM-100201
Description: IV Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study: NCT01322503

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus
Description: Norovirus challenge pool administered to each subject

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus
Description: Norovirus challenge pool administered to each subject
Study: NCT02075489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure treatment.
Description: Acupressure will be provided 40 min/day, 2 days/week for 6 weeks (total of 12 sessions). Symptomatic veterans will receive standardized acupressure treatment for \~5 s on each acupoint until the subject gets the sense of soreness and numbness, and the procedure will be repeated three times. Kneading massage will be applied around eyes and forehead, and face will be swabbed by palm for \~ 5 min. Manipulation of these acupoints is aimed at helping to calm and ease the subject, lighten headache and migraine, relieve fatigue, and alleviate insomnia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reiki
Description: Veterans in the control group will receive reiki treatment with the same dosage (40 min/session, 12 sessions in 6 wks). The practitioner will place his/her hands on the recipient in various positions covering head, the back of the torso, and the 4 limbs with fixed set of 12 hand positions. These covered areas will then be tapped and stroked, and practitioner will focus his/her gaze on these areas for 2-3 min, through which the healing energy is transferred to the subjects. In a format similar to acupressure treatment, it will be used as an inert control treatment to balance additional care the experimental group will receive.
Study: NCT00853320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride tablet 15 mg
Description: Oxycodone hydrochloride tablet 15 mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roxicodone™ tablet 15 mg
Description: Roxicodone™ tablet 15 mg, single dose fasting
Study: NCT00839384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advisa IPG
Description: Implantable Pulse Generator will be implanted
Study: NCT04186975

Intervention type: DEVICE
Intervention: Non-Invasive fetal ECG
Description: Non-Invasive fetal ECG

Intervention type: DEVICE
Intervention: Non-Invasive fetal ECG
Description: Non-Invasive fetal ECG

Intervention type: DEVICE
Intervention: Fetal heart rate monitor
Description: Fetal heart rate monitor

Intervention type: DEVICE
Intervention: Fetal heart rate monitor
Description: Fetal heart rate monitor
Study: NCT00163267

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: clopidogrel
Description: Best endovascular treatment either with one or the other drug arm should be investigated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Best endovascular treatment either with one or the other drug arm should be investigated
Study: NCT00587002

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVUS
Description: Intravascular ultrasound with virtual histology
Study: NCT01011439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milciclib Maleate
Description: 150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity.
Study: NCT00359021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC125
Description: 200 mg twice daily until commercially available
Study: NCT02771509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANG-3777
Description: 6 mg/mL BB3, IV, 4 days in a row, first dose must be within 4 hours after surgery, the next three doses will be approx. 24 hours after the last dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT03137589

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedical support
Description: Participating sites will be advised by telemedicine support.
Study: NCT03941678

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: 0.3 g/kg/day for 7 days; 0.1 g/kg/day for 63 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.3 g/kg/day for 7 days; 0.1 g/kg/day for 63 days
Study: NCT02328651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin plus Xiao'er jiebiao oral liquid
Description: For mild (Phase I) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, ivgg, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.~For moderate (Phase II) patients:~recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2\~5ml/kg,iv, Bid\~tid）

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: For mild (PhaseI) patients : recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip.~For moderate (PhaseII) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2\~5ml/kg, iv, Bid\~tid）
Study: NCT02161575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intraveal injections of 0.5mg ranibizumab
Study: NCT01735253

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic roux en Y gastric bypass / open duodenojejunal bypass
Description: routine GBP with 80cm roux and biliopancreatic limb
Study: NCT02443649

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene program
Description: Sleep hygiene program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene program
Description: Sleep hygiene program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hypnosis
Description: Hypnosis recording with personalized goals and imagery for sleep improvement
Study: NCT04668053

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional training protocol
Description: Mobility and core strengthening and the steps and lunges As per athletes requirement Body weight squat with 12 reps, Body weight split squat with 8 each side, Bilateral hip raise with 12 reps, Push-up with15 reps and Cricket related skills as per coach advised

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip flexor resistance protocol
Description: Warm up prior to training The loop bands (Resistance-band©) that were used are in several colors-Red, black, yellow, blue and green extended from strongest type to weakest.~Athletes executed 3 training sessions of 3 sets per week for 6 weeks.~The relative load was:~Week 1----15 RM Week 2-4----10 RM Week 5-6----8 RM The Therapist has ensured a concentric contraction of 3-s, an isometric contraction of 2-s, eccentric contraction of 3-s, rest for 2-s prior to the next repetition and rest for 2-min prior the next set.~It took 10 min to complete each session, with rest between sets.
Study: NCT02237963

Intervention type: PROCEDURE
Intervention: Posterolateral thoracotomy

Intervention type: PROCEDURE
Intervention: Axillary thoracotomy
Study: NCT00646906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin First
Description: Crossover period Aspirin First: Subjects will receive 81 mg aspirin at approximately 8 am followed by acetaminophen at approximately 10 am.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin First
Description: Crossover period Aspirin First: Subjects will receive 81 mg aspirin at approximately 8 am followed by acetaminophen at approximately 10 am.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Last
Description: Crossover period Aspirin Last: Subjects will receive acetaminophen at approximately 8 am followed by 81 mg aspirin at approximately 10 am.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Last
Description: Crossover period Aspirin Last: Subjects will receive acetaminophen at approximately 8 am followed by 81 mg aspirin at approximately 10 am.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg/d
Description: Subjects will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 4000 mg/d
Description: Crossover period Acetaminophen 4000 mg/d: Acetaminophen (1000 mg p.o.) orally at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg/d
Description: Crossover period Ibuprofen 800 mg/d: Ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.
Study: NCT04524702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Given IV
Study: NCT01797497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care plan and coaching
Description: In the intervention group, primary care providers and parents complete their sections of the referral care plan. Parents and referred specialists receive a copy of the form. Parents receive a 5-10 minute brief intervention by phone consisting of education and coaching. The care plan is reviewed with parents to help them practice exchanging information with the specialist and encourage parents to contact their child's primary care provider with any further questions. At the specialist visit, specialists review and complete the care plan with the parent and return the plan to the referring primary care provider. Outcome data are collected from parents before and after the specialist visit.
Study: NCT00652730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone HCl
Description: Tablets, 30 mg, single-dose, fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone HCl
Description: Tablets, 30 mg, single-dose, fed conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspar
Description: Tablets, 30 mg, single-dose, fed conditions
Study: NCT03725124

Intervention type: OTHER
Intervention: Interview
Description: Participants will be interviewed on their experience of family planning and inflammatory bowel disease.

Intervention type: OTHER
Intervention: Interview
Description: Participants will be interviewed on their experience of family planning and inflammatory bowel disease.

Intervention type: OTHER
Intervention: Interview
Description: Participants will be interviewed on their experience of family planning and inflammatory bowel disease.
Study: NCT04673591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tregalizumab
Description: a monoclonal antibody designed for the treatment of allergic asthma indication

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo
Study: NCT02512406

Intervention type: OTHER
Intervention: The Sensory Profile
Description: 60 item questionnaire administered to participants age 6-10 with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.

Intervention type: OTHER
Intervention: The Adult/Adolescent Sensory Profile
Description: 60 item questionnaire administered to participants age 11 and older with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.

Intervention type: OTHER
Intervention: Children's Yale-Brown Obsessive Compulsive Scale
Description: 10-item symptom checklist questionnaire administered by a physician to participants aged 6-14. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.

Intervention type: OTHER
Intervention: Yale-Brown Obsessive Compulsive Scale
Description: 10-item symptom checklist questionnaire administered by a physician to participants aged 15 and older. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.

Intervention type: OTHER
Intervention: Yale Global Tic Severity Scale
Description: Clinician administered questionnaire given to all participants. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.

Intervention type: OTHER
Intervention: Demographic Data
Description: Data will be collected including: Age, duration of symptoms, presence or absence of autism spectrum disorder, presence or absence of OCD, presence or absence of ADHD.
Study: NCT02201420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc 99m tilmanocept
Study: NCT04526743

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Psychological and behavioral variables will be collected using questionnaires that have been validated in our setting and will be completed by the patients themselves online.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Psychological and behavioral variables will be collected using questionnaires that have been validated in our setting and will be completed by the patients themselves online.
Study: NCT00113230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin (Bevacizumab, RHUMAB VEGF)
Description: Starting Dose 5 mg/kg intravenously on day one of radiotherapy, given every 2 weeks +/- 2 days for a total of 3 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 900 mg/m\^2 by mouth twice a day during days of radiation for all five weeks of therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 45 Gy in 25 fractions to the pelvis followed by 5.4 Gy as a boost dose to the primary tumor with margin, for a total dose of 50.4 Gy over 28 treatment days.
Study: NCT05407233

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Does not reuse the syringe for insulin application
Description: Does not reuse needles for insulin application Patients will be given quantity of needles for use during the study period according to the allocated group and a collector for sharps descarpack to collect the used syringes and needles. Initially, all patients will be instructed on the indication and importance of insulin use, aspects of conservation, preparation and administration, reviewing the dose aspirated in the syringe. They will also be instructed in relation to the use of the collector for sharps. Patients will also receive the booklet specially designed for this registry where they must indicate the number of hematomas, bruises, lipodystrophies, or inflammation that they identify whenever they occur. This booklet will be given to the team of researchers at each visit (monthly), who will review the records with the patient and guide them for subsequent completion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uses the syringe for insulin delivery five times
Description: Uses the needles for insulin application five times. Patients will be given quantity of needles for use during the study period according to the allocated group and a collector for sharps descarpack to collect the used syringes and needles. Initially, all patients will be instructed on the indication and importance of insulin use, aspects of conservation, preparation and administration, reviewing the dose aspirated in the syringe. They will also be instructed in relation to the use of the collector for sharps. Patients will also receive the booklet specially designed for this registry where they must indicate the number of hematomas, lipodystrophies, or inflammation that they identify whenever they occur. This booklet will be given to the team of researchers at each visit (monthly), and they will review the records with the patient and guide them for subsequent completion.
Study: NCT00797875

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PNF stretching
Description: PNF stretching x 5 repetitions and continue 3 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: passive stretching
Description: passive stretching x 5 repetitions continue 3 days
Study: NCT02230254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention PROMUS PREMIER
Description: PROMUS PREMIER
Study: NCT02324959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RehaCom
Description: The computer-based neurorehabilitation program is intended for patients with acquired cognitive deficits after brain damage, e.g. after stroke. The RehaCom software has five different therapeutic groups aimed at restoration of attention, memory, executive functions, and visual field, respectively. Each group has one to four different modules to choose from for each therapy session. Only attention will be trained in this study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RehaCom
Description: The computer-based neurorehabilitation program is intended for patients with acquired cognitive deficits after brain damage, e.g. after stroke. The RehaCom software has five different therapeutic groups aimed at restoration of attention, memory, executive functions, and visual field, respectively. Each group has one to four different modules to choose from for each therapy session. Only attention will be trained in this study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The affected meridian group is treated by needling on Baihui (GV20\|DU20) and Shenting (GV24\|DU24) - both acupoints of the Governor Vessel. Baihui is 5 cun (1cun=3.33 cm) superior to the anterior hairline on the anterior median line (midpoint of the connecting line between the auricular apices).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: The affected meridian group is treated by needling on Baihui (GV20\|DU20) and Shenting (GV24\|DU24) - both acupoints of the Governor Vessel. Baihui is 5 cun (1cun=3.33 cm) superior to the anterior hairline on the anterior median line (midpoint of the connecting line between the auricular apices).
Study: NCT02615483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based platform
Description: The WP is based on a conducted literature review and results form a previous study conducted in the regional context of the study. Information on the WP is animated based on the current literature stating that educative animation video optimises patients' acquisition of knowledge. The intention is to offer the patients the advantages in gaining knowledge in familiar surroundings and at a pace matching their needs and wishes.~The WP contains animated and written information mirroring the course of treatment, frequently asked questions and answers, it contains animated training support, a diary in order to keep track of training and development of pain and finally a social feature, a web-café.
Study: NCT03092206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: antiretroviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: antiretroviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R/F/TAF
Description: antiretroviral therapy